Larry H Matherly

USPTO Granted Patents = 14 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Farmington Hills, MI (US) (2012 - 2016)
Farmington Hill, MI (US) (2017)
Novi, MI (US) (2016 - 2022)

Company Filing History:

11 out of 579

Wayne State University

patents

8 out of 69

Duquesne University of the Holy Spirit

patents

6 out of 70

Duquesne University of the Holy Ghost

patents

where one patent can have more than one assignee

Years Active: 2012-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11384084 - First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents (2022-07-12),

2. 11053252 - Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same (2021-07-06),

3. 10793573 - First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents (2020-10-06),

4. 10611767 - Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same (2020-04-07),

5. 10167287 - Substituted pyrimidine compounds and methods of use and manufacture (2019-01-01),

6. 10000498 - Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same (2018-06-19),

7. 9650384 - Substituted pyrimidine compounds and methods of use and manufacture (2017-05-16),

8. 9511069 - Selective proton coupled folate transporter and folate receptor, and GRAFTase inhibitor compounds and methods of using the same (2016-12-06),

9. 9481678 - Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors (2016-11-01),

10. 9446045 - Methods of using selective chemotherapeutic agents for targeting tumor cells (2016-09-20),

11. 8952019 - Methods of using selective chemotherapeutic agents for targeting tumor cells (2015-02-10),

12. 8552014 - Methods of using selective chemotherapeutic agents for targeting tumor cells (2013-10-08),

13. 8258143 - Methods of using substituted pyrrolo[2,3-d]pyrimidines for targeting tumor cells and treating cancer (2012-09-04),

14. 8252804 - Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same (2012-08-28),

Title: Spotlight on Larry H Matherly: Pioneering Cancer Treatment Innovations

Introduction:

Larry H Matherly, hailing from Novi, MI (US), is a distinguished inventor with a remarkable portfolio of 14 patents. His groundbreaking work in the field of cancer treatment has garnered significant attention in the scientific community.

Latest Patents:

Matherly's latest patents include 'First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents'. These innovative compounds hold the potential to revolutionize cancer therapy by targeting specific pathways crucial for tumor growth and progression. Another notable patent is 'Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds', which offers promising avenues for treating cancer and autoimmune diseases.

Career Highlights:

Throughout his career, Matherly has made significant contributions while working at Wayne State University and Duquesne University of the Holy Spirit. His dedication to research and development in the biomedical field has paved the way for novel therapeutic strategies in cancer treatment.

Collaborations:

Matherly has collaborated with esteemed researchers in the field, including his coworker Aleem Gangjee. Their partnership has led to the development of innovative compounds targeting specific receptors and enzymes involved in cancer progression, demonstrating the power of teamwork in driving scientific advancement.

Conclusion:

Larry H Matherly's relentless pursuit of innovation and his commitment to advancing cancer treatment methodologies have established him as a trailblazer in the field of biomedical research. His patents and collaborative efforts underscore the importance of interdisciplinary approaches in tackling complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.